CureVacCVAC
CVAC
About: CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
Employees: 1,088
0
Funds holding %
of 7,429 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
185% more capital invested
Capital invested by funds: $21.8M [Q1] → $62.2M (+$40.4M) [Q2]
67% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 15
8% more funds holding
Funds holding: 83 [Q1] → 90 (+7) [Q2]
1.67% more ownership
Funds ownership: 3.51% [Q1] → 5.18% (+1.67%) [Q2]
4% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 25
80% less call options, than puts
Call options by funds: $552K | Put options by funds: $2.76M
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$5
7%
downside
Avg. target
$6.83
27%
upside
High target
$10
85%
upside
3 analyst ratings
1 positive
33%
2 neutral
67%
0 negative
0%
UBS Eliana Merle | 2%upside $5.50 | Neutral Downgraded | 26 Jun 2025 |
Jefferies Roger Song | 7%downside $5 | Hold Downgraded | 13 Jun 2025 |
JMP Securities Roy Buchanan | 85%upside $10 | Market Outperform Reiterated | 28 May 2025 |
Financial journalist opinion
Based on 3 articles about CVAC published over the past 30 days
Neutral
Accesswire
1 week ago
CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates
CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates Entered into a definitive Purchase Agreement pursuant to which BioNTech intends to acquire all shares of CureVac, uniting two highly complementary German companies to bring transformative mRNA-based treatments to patients globally Entered into agreements to resolve and dismiss all pending patent litigation in the U.S. with Pfizer/BioNTech related to mRNA-based COVID-19 vaccines and to set a framework for resolving related ongoing patent disputes outside the U.S. upon closing of BioNTech's acquisition of CureVac Received Clinical Trial Application (CTA) clearance from the European Medicines Agency (EMA) for CVHNLC, a proprietary off-the-shelf cancer immunotherapy candidate targeting squamous non-small cell lung cancer (sqNSCLC) CVGBM glioblastomadata from Part B of Phase 1 remain on track for H2 2025 Strong cash and cash equivalents position of €392.7 million as of June 30, 2025; expected cash runway into 2028 TÜBINGEN, GERMANY AND BOSTON, MA / ACCESS Newswire / August 15, 2025 / CureVac N.V. (Nasdaq:CVAC), a pioneering multinational biotech company developing a new class of transformative medicines based on messenger RNA (mRNA), today announced financial results for the second quarter and first half of 2025 and provided a business update.
Positive
Proactive Investors
2 weeks ago
GSK secures $370 million settlement and future royalties in CureVac mRNA patent dispute
GSK PLC (LSE:GSK, NYSE:GSK) will receive an upfront payment of $370 million from CureVac, following a patent settlement involving BioNTech and Pfizer over messenger ribonucleic acid (mRNA) vaccine technology. The deal will also see GSK collect a 1% royalty on United States sales of Pfizer and BioNTech's influenza, COVID-19, and related combination mRNA vaccines from the start of 2025.
Positive
Reuters
2 weeks ago
CureVac settles patent dispute litigation with Pfizer and BioNTech
CureVac said on Thursday that the company and GSK have entered an agreement to a resolve patent dispute with Pfizer and BioNTech related to mRNA-based COVID-19 vaccines.
Neutral
Accesswire
2 months ago
CureVac Announces Voting Results of General Meeting
TÜBINGEN, GERMANY AND BOSTON, MA / ACCESS Newswire / June 24, 2025 / CureVac N.V. (NASDAQ:CVAC), a pioneering multinational biotech company developing a new class of transformative medicines based on messenger RNA (mRNA), today announced the voting results of the Company's Annual General Meeting.
Positive
Zacks Investment Research
2 months ago
CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech
CVAC jumps 41% in a month after signing a $1.25B deal to be acquired by BioNTech to accelerate mRNA therapy development.
Neutral
GlobeNewsWire
2 months ago
$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of CureVac N.V. (NASDAQ: CVAC)
NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating CureVac N.V. (NASDAQ: CVAC ) related to its sale to BioNTech SE. Under the terms of the proposed transaction, each CureVac share will be exchanged for approximately $5.46 in BioNTech ADSs. Upon closing of the proposed transaction, CureVac shareholders are expected to own between 4% and 6% of BioNTech. Is it a fair deal?
Neutral
GlobeNewsWire
2 months ago
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVAC, KNW, SOAR, HLGN on Behalf of Shareholders
NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Negative
Investopedia
2 months ago
Top Stock Movers Now: Oracle, Boeing, CureVac, and More
U.S. equities were mixed and little changed at midday as another key measure of inflation, the Producer Price Index (PPI), came in lower than expected. The S&P 500 and Nasdaq advanced, while the Dow Jones Industrial Average was lower.
Positive
Schaeffers Research
2 months ago
CureVac Stock Soars on BioNTech Buyout
Biotech stock CureVac NV (NASDAQ:CVAC) was last seen up 32.2% at $5.37, after news that BioNTech (BNTX) is acquiring the company in all-stock deal worth $1.25 billion.
Positive
Benzinga
2 months ago
BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal
BioNTech SE BNTX on Thursday agreed to acquire CureVac N.V. CVAC in an all-stock transaction.
Charts implemented using Lightweight Charts™